234 citations
,
September 2004 in “Clinical cancer research” BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.
124 citations
,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
99 citations
,
July 2017 in “Clinical Reviews in Allergy & Immunology” New treatments for Alopecia Areata show promise but need to be more effective and affordable.
50 citations
,
January 2016 in “The FEBS journal” RANK is a key target in breast cancer treatment due to its role in tumor growth and bone metastasis.
47 citations
,
October 2014 in “Expert Opinion on Emerging Drugs” New alopecia treatments aim for better results and fewer side effects.
44 citations
,
September 2014 in “Cell Death & Differentiation” Tumor suppressors help control inflammation in cancer and restoring their function could lead to new treatments.
41 citations
,
December 2015 in “JAMA Dermatology” Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.
39 citations
,
January 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
37 citations
,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
24 citations
,
July 2021 in “Pharmaceutics” Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
24 citations
,
January 2018 in “International Journal of Trichology” Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
15 citations
,
March 2021 in “Journal of clinical medicine” Biologic treatments for Crohn's disease and ulcerative colitis can cause skin problems, and doctors should adjust treatment if these occur.
15 citations
,
June 2020 in “Processes” CMX from Centipeda minima can significantly improve hair growth in mild to moderate balding.
7 citations
,
August 2023 in “Journal of the American Academy of Dermatology” JAK inhibitors offer new hope for treating severe alopecia areata.
6 citations
,
January 2023 in “npj regenerative medicine” Transplanting growing hair follicles into scars can help regenerate and improve scar tissue.
6 citations
,
November 2022 in “Journal of autoimmunity” JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.
2 citations
,
November 2019 in “Skin appendage disorders” Platelet-rich plasma doesn't prevent hair loss from chemotherapy, and mononuclear cells only help against hair loss from one specific chemotherapy drug.
2 citations
,
April 2019 in “Dermatologic Therapy” A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
1 citations
,
December 2023 in “Molecules/Molecules online/Molecules annual” JAK inhibitors show promise for treating various skin diseases.
1 citations
,
May 2023 in “Prospects in Pharmaceutical Sciences” New cytokine-targeted therapies show promise for treating alopecia areata.
1 citations
,
September 2022 in “Nepal journal of dermatology, venereology & leprology” Apremilast shows promise for several skin conditions but needs more research.
1 citations
,
February 2021 in “Farmacja Polska” Janus kinase inhibitors show promise in treating autoimmune skin diseases.
1 citations
,
March 2011 in “Informa Healthcare eBooks” Hormonal therapy is effective for treating acne in adult women, especially with signs of high androgen levels.
January 2026 in “Medicina” JAK inhibitors show promise for treating various skin disorders effectively and safely.
January 2026 in “Frontiers in Molecular Biosciences” A new method helps diagnose alopecia areata using specific gene markers and could guide targeted treatments.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
January 2025 in “Balkan Medical Journal” Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.
December 2024 in “Cureus” Baricitinib treatment for alopecia universalis can cause hair regrowth with unexpected whitening.
October 2024 in “Clinical Cosmetic and Investigational Dermatology” Brevilin-A is a safe and effective treatment for mild to moderate alopecia areata in children.
April 2022 in “Biomedicine & Pharmacotherapy” CXCL12 protein slows down hair growth through its receptor CXCR4. Blocking this can potentially increase hair growth.